• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Home
  • LinkedIn
  • Twitter

  • About Us
    • Overview
    • Executive Committee
    • Board Of Directors
    • Partners
  • Science
    • Overview
    • Approach
    • Technology
      • shRNA
      • shARC Platform
    • Scientific Publications
  • Pipeline
  • Newsroom
    • Press Releases
    • Events
    • Media Center
  • Investors
    • Overview
    • Analyst Coverage
    • Corporate Governance
    • Regulated Information
    • Shareholders Information
    • Shareholders Meeting
  • Careers
  • Contact Us
  • Home
  • Newsroom
  • Media Center

Media Center

Discover what is our current strategy and main research platforms

Corporate Slide deck

What is the difference between autologous and allogeneic CAR T-cell therapies?

Allogeneic vs. Autologous Fact Sheet

What is NKG2D and where is it expressed?

NKG2D Fact Sheet

What is the shRNA technology and how can it be used for allogeneic cell therapies?

shRNA Fact Sheet

What is multiplexing of shRNAs and why is that important?

Multiplexing shRNA Fact Sheet

Dual targeting CAR T-cells: what for?

Dual CAR Fact Sheet

What is B7-H6 and where is it expressed?

B7-H6 Fact Sheet

What is the TIM Technology included in CYAD-101?

TIM Fact Sheet

What are the differences between CAR T-cell and CAR NK cell therapies?

CAR T vs NK Cells

Hairpins and Scissors – Delivering a Non-Gene Edited Allogeneic CAR T Cell Therapy for the Masses White Paper (2020)

White Paper

Development of the Next Generation NKG2D CAR T-cell Manufacturing Process White Paper (2019)

White Paper

CAR T NKR-2: Leveraging the Breadth of Innate Immunity White Paper (2017)

White Paper

Celyad Oncology Logo

Load More

Footer

Celyad Oncology

Celyad Oncology Logo
  • About
  • Science
  • Pipeline
  • Newsroom
  • Investors
  • Contact Us
  • LinkedIn
  • Twitter

Copyright © 2020 All Rights Reserved.

  • Cookie Policy |
  • Privacy Policy |
  • Terms of Use